Advances in pharmacotherapy for hyperphosphatemia in renal disease

Bibliography

• Duranton F, Cohen G, De Smet R, et al. Normal and pathologic concentrations of uremic toxins. J Am Soc Nephrol 2012;23(7):1258-70
   PubMed Web of Science ®Google Scholar
• Voormolen N, Noordzij M, Grootendorst DC, et al. High plasma phosphate as a risk factor for decline in renal function and mortality in pre-dialysis patients. Nephrol Dial Transplant 2007;22:2909-16
   PubMed Web of Science ®Google Scholar
• Vanholder R, Baurmeister U, Brunet P, et al. A bench to bedside view of uremic toxins. J Am Soc Nephrol 2008;19(5):863-70
   PubMed Web of Science ®Google Scholar
• Spasovski G, Massy Z, Vanholder R. Phosphate metabolism in chronic kidney disease: from pathophysiology to clinical management. Semin Dial 2009;22(4):357-62
   PubMed Web of Science ®Google Scholar
• Spasovski G. A review of sevelamer hydrochloride in end-stage renal disease patients on dialysis. Clinical Medicine Insights: Therapeutics 2011:3:51-5
   Google Scholar
• Goto S, Komaba H, Fukagawa M, Nishi S. Optimizing the cost-effectiveness of treatment for chronic kidney disease-mineral and bone disorder. Kidney Int Suppl 2013;3:457-61
   Web of Science ®Google Scholar
• Moe SM, Drueke TB, Block GA, et al. Kidney Disease: Improving Global Outcomes CKDMBDWG. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease - Mineral and Bone Disorder (CKD-MBD). Kidney Int 2009;76:S1-S130
   Google Scholar
• Ketteler M, Elder GJ, Evenepoel P, et al. Revisiting KDIGO clinical practice guideline on chronic kidney disease-mineral and bone disorder: a commentary from a Kidney Disease: Improving Global Outcomes controversies conference. Kidney Int 2015;87(3):502-28
   PubMed Web of Science ®Google Scholar
• National Kidney Foundation. K/DOQI, NKF: clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003;42:S1-201
   PubMedGoogle Scholar
• Bleyer AJ, Burke SK, Dillon M, et al. A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients. Am J Kidney Dis 1999;33(4):694-701
   PubMed Web of Science ®Google Scholar
• Kurz P, Monier-Faugere MC, Bognar B, et al. Evidence for abnormal calcium homeostasis in patients with adynamic bone disease. Kidney Int 1994;46:855-61
   PubMed Web of Science ®Google Scholar
• Chertow GM, Burke SK, Raggi P. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002;62(1):245-52
   PubMed Web of Science ®Google Scholar
• Zoccali C, Abramowicz D, Cannata - Andia JB, et al. European best practice quo vadis? From European best practice guidelines (EBPG) to European renal best practice (ERBP). Nephrol Dial Transplant 2008;23:2162-6
   PubMed Web of Science ®Google Scholar
• Goldsmith DJ, Covic A, Fouque D, et al. Endorsement of the Kidney Disease Improving Global Outcomes (KDIGO) Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guidelines: a European Renal Best Practice (ERBP) commentary statement. Nephrol Dial Transplant 2010;25(12):3823-31
   PubMed Web of Science ®Google Scholar
• Uhlig K, Berns JS, Kestenbaum B, et al. KDOQI US commentary on the 2009 KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of CKD-Mineral and Bone Disorder (CKD-MBD). Am J Kidney Dis 2010;55(5):773-99
   PubMed Web of Science ®Google Scholar
• Manns BJ, Hodsman A, Zimmerman DL, et al. Canadian Society of Nephrology commentary on the 2009 KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of CKD-Mineral and Bone Disorder (CKD-MBD). Am J Kidney Dis 2010;55(5):800-12
   PubMed Web of Science ®Google Scholar
• London G, Coyne D, Hruska K, et al. The new kidney disease: improving global outcomes (KDIGO) guidelines - expert clinical focus on bone and vascular calcification. Clin Nephrol 2010;74(6):423-32
   PubMed Web of Science ®Google Scholar
• Spasovski GB. Bone health and vascular calcification relationships in chronic kidney disease. Int Urol Nephrol 2007;39(4):1209-16
   PubMed Web of Science ®Google Scholar
• Spasovski G, Gelev S, Masin-Spasovska J, et al. Improvement of bone and mineral parameters related to adynamic bone disease by diminishing dialysate calcium. Bone 2007;41(4):698-703
   PubMed Web of Science ®Google Scholar
• Spasovski G. New strategies in treatment of mineral and bone disorders and associated cardiovascular disease in patients with chronic kidney disease. Recent Patents Cardiovasc Drug Discov 2008;3(3):222-8
   PubMedGoogle Scholar
• Farkouh ME, Fuster V. Meta -analysis of small trials: proceed with caution. Nat Clin Pract Nephrol 2008;4:115
   PubMedGoogle Scholar
• Tonelli M, Wiebe N, Culleton B, et al. Alberta Kidney Disease Network. Systematic review of the clinical efficacy and safety of sevelamer in dialysis patients. Nephrol Dial Transplant 2007;22:2856-66
   PubMed Web of Science ®Google Scholar
• Manns B, Klarenbach S, Lee H, et al. Economic evaluation of sevelamer in patients with end-stage renal disease. Nephrol Dial Transplant 2007;22(10):2867-78
   PubMed Web of Science ®Google Scholar
• Block GA, Raggi P, Bellasi A, et al. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int 2007;71(5):438-41
   PubMed Web of Science ®Google Scholar
• Suki WN, Zabaneh R, Cangiano JL, et al. Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. Kidney Int 2007;72(9):1130-7
   PubMed Web of Science ®Google Scholar
• St Peter WL, Liu J, Weinhandl E, Fan Q. A comparison of sevelamer and calcium-based phosphate binders on mortality, hospitalization, and morbidity in hemodialysis: a secondary analysis of the Dialysis Clinical Outcomes Revisited (DCOR) randomized trial using claims data. Am J Kidney Dis 2008;51(3):445-54
   PubMed Web of Science ®Google Scholar
• Ferreira A, Frazão JM, Monier-Faugere MC, et al. Effects of sevelamer hydrochloride and calcium carbonate on renal osteodystrophy in hemodialysis patients. J Am Soc Nephrol 2008;19(2):405-12
   PubMed Web of Science ®Google Scholar
• Assimon MM, Mousa S, Shaker O, Pai AB. The effect of sevelamer hydrochloride and Calcium–based phosphate binders on mortality in hemodialysis patients: a need for more research. Consult Pharm 2010;25(1):41-54
   PubMedGoogle Scholar
• Jamal SA, Fitchett D, Lok CE, et al. The effects of calcium-based versus non-calcium-based phosphate binders on mortality among patients with chronic kidney disease: a meta-analysis. Nephrol Dial Transplant 2009;24(10):3168-74
   PubMed Web of Science ®Google Scholar
• Qunibi W, Moustafa M, Muenz LR, et al. A 1-year randomized trial of calcium acetate versus sevelamer on progression of coronary artery calcification in hemodialysis patients with comparable lipid control: the Calcium Acetate Renagel Evaluation-2 (CARE-2) study. Am J Kidney Dis 2008;51:952-65
   PubMed Web of Science ®Google Scholar
• Barreto DV, Barreto FD, de Carvalho AB, et al. Phosphate binder impact on bone remodeling and coronary calcification–results from the BRiC Study. Nephron Clin Pract 2008;110:c273-83
   PubMed Web of Science ®Google Scholar
• Shantouf R, Ahmadi N, Flores F, et al. Impact of phosphate binder type on coronary artery calcification in hemodialysis patients. Clin Nephrol 2010;74(1):12-18
   PubMed Web of Science ®Google Scholar
• Brandenburg VM, Schlieper G, Heussen N, et al. Serological cardiovascular and mortality risk predictors in dialysis patients receiving sevelamer: a prospective study. Nephrol Dial Transplant 2010;25(8):2672-9
   PubMed Web of Science ®Google Scholar
• Zhang Q, Li M, Lu Y, et al. Meta-analysis comparing sevelamer and calcium-based phosphate binders on cardiovascular calcification in hemodialysis patients. Nephron Clin Pract 2010;115(4):c259-67
   Google Scholar
• Fishbane S, Delmez J, Suki WN, et al. A randomized, parallel, open-label study to compare once-daily sevelamer carbonate powder dosing with thrice-daily sevelamer hydrochloride tablet dosing in CKD patients on hemodialysis. Am J Kidney Dis 2010;55(2):307-15
   PubMed Web of Science ®Google Scholar
• De Francisco AL, Leidig M, Covic A, et al. Evaluation of calcium acetate/magnesium carbonate as a phosphate binder compared with sevelamer hydrochloride in haemodialysis patients: a controlled randomized study (CALMAG study) assessing efficacy and tolerability. Nephrol DialTransplant 2010;25:3707-17
   PubMed Web of Science ®Google Scholar
• Spasovski G, Vanholder R. Is combined calcium/magnesium phosphate binder really non-inferior to sevelamer hydrochloride? Nephrol DialTransplant 2011;26(4):1442-3
   PubMed Web of Science ®Google Scholar
• Negri AL. Phosphate binders, cardiovascular calcifications and mortality: do we need another survival study with sevelamer? J Nephrol 2010;23(6):653-7
   PubMed Web of Science ®Google Scholar
• White CA, Jaffey J, Magner P. Cost of applying the K/DOQI guidelines for bone metabolism and disease to a cohort of chronic hemodialysis patients. Kidney Int 2007;71:312-17
   PubMed Web of Science ®Google Scholar
• Bover J, Evenepoel P, Ureña-Torres P, et al. Opponent’s comments. Nephrol Dial Transplant 2015;30(3):357
   PubMed Web of Science ®Google Scholar
• Jamal SA, Vandermeer B, Raggi P, et al. Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta-analysis. Lancet 2013;382(9900):1268-77
   PubMed Web of Science ®Google Scholar
• Navaneethan SD, Palmer SC, Vecchio M, et al. Phosphate binders for preventing and treating bone disease in chronic kidney disease patients. Cochrane Database Syst Rev 2011;(2):CD006023
   Google Scholar
• Cannata-Andía JB, Fernández-Martín JL, Locatelli F, et al. Use of phosphate-binding agents is associated with a lower risk of mortality. Kidney Int 2013;84(5):998-1008
   PubMed Web of Science ®Google Scholar
• Hill KM, Martin BR, Wastney ME, et al. Oral calcium carbonate affects calcium but not phosphorus balance in stage 3-4 chronic kidney disease. Kidney Int 2013;83:959-66
   PubMed Web of Science ®Google Scholar
• Block GA, Wheeler DC, Persky MS, et al. Effects of phosphate binders in moderate CKD. J Am Soc Nephrol 2012;23:1407-15
   PubMed Web of Science ®Google Scholar
• Di Iorio B, Bellasi A, Russo D. Mortality in kidney disease patients treated with phosphate binders: a randomized study. Clin J Am Soc Nephrol 2012;7:487-93
   PubMed Web of Science ®Google Scholar
• Oliveira RB, Cancela AL, Graciolli FG, et al. Early Control of PTH and FGF23 in Normophosphatemic CKD Patients: A New Target in CKD-MBD Therapy? Clin J Am Soc Nephrol 2010;5(2):286-91
   PubMed Web of Science ®Google Scholar
• De Broe ME, Coburn JW. Aluminum and Renal Failure. In: Developments in Nephrology 26. Kluwer Acad Publ, Dordrecht; 1990. p. 99-375
   Google Scholar
• Sheikh MS, Maquire JA, Emmett M, et al. Reduction of dietary phosphorus absorption by phosphorus binders. A theoretical, in vitro, and in vivo study. J Clin Invest 1989;83(1):66-73
   PubMed Web of Science ®Google Scholar
• Goodman WG, Goldin J, Kuizon BD, et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000;342(20):1478-83
   PubMed Web of Science ®Google Scholar
• CARE. Qunibi WY, Hootkins RE, McDowell LL, et al. Treatment of hyperphosphatemia in hemodialysis patients: the Calcium Acetate Renagel Evaluation (CARE Study). Kidney Int 2004;65:1914-26
   PubMed Web of Science ®Google Scholar
• Jean G, Lataillade D, Genet L, et al. Calcium carbonate, but not sevelamer, is associated with better outcomes in hemodialysis patients: results from the French ARNOS study. Hemodial Int 2011;15:485-92
   PubMed Web of Science ®Google Scholar
• Qunibi W, Moustafa et al.Muenz LR, et al. A 1-year randomized trial of calcium acetate versus sevelamer on progression of coronary artery calcification in hemodialysis patients with comparable lipid control: the Calcium Acetate Renagel Evaluation-2 (CARE-2) study. Am J Kidney Dis 2008;51(6):952-65
   PubMed Web of Science ®Google Scholar
• Ketteler M, Rix M, Fan S, et al. Efficacy and tolerability of sevelamer carbonate in hyperphosphatemic patients who have chronic kidney disease and are not on dialysis. Clin J Am Soc Nephrol 2008;3:1125-30
   PubMed Web of Science ®Google Scholar
• Savica V, Santoro D, Monardo P, et al. Sevelamer carbonate in the treatment of hyperphosphatemia in patients with chronic kidney disease on hemodialysis. Ther Clin Risk Manag 2008;4(4):821-6
   PubMedGoogle Scholar
• Chertow GM, Burke SK, Raggi P; Treat to Goal Working Group. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002;62:245-52
   PubMed Web of Science ®Google Scholar
• Block GA, Spiegel DM, Ehrlich J, et al. Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int 2005;68:1815-24
   PubMed Web of Science ®Google Scholar
• Hutchison AJ, Laville M; On behalf of the SPD405-313 lanthanum study group. Switching to lanthanum carbonate monotherapy provides effective phosphate control with a low tablet burden. Nephrol Dial Transplant 2008;23(11):3677-84
   PubMed Web of Science ®Google Scholar
• D’Haese PC, Spasovski GB, Sikole A, et al. A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients. Kidney Int Suppl 2003;85:S73-8
   PubMedGoogle Scholar
• Sakurada T, Oishi D, Shibagaki et al. Efficacy of oral powder compared with chewable tablets for lanthanum carbonate administration in hemodialysis patients. Hemodial Int 2013;17(Suppl 1):S2-6
   Google Scholar
• Toussaint ND, Lau KK, Polkinghorne KR, Kerr PG. Attenuation of aortic calcification with lanthanum carbonate versus calcium-based phosphate binders in haemodialysis: A pilot randomized controlled trial. Nephrology (Carlton) 2011;16(3):290-8
   PubMed Web of Science ®Google Scholar
• Lacour B, Lucas A, Auche` re D, et al. Chronic renal failure is associated with increased tissue deposition of lanthanum after 28-day oral administration. Kidney Int 2005;67:1062-9
   PubMed Web of Science ®Google Scholar
• Hutchison AJ, Barnett ME, Krause R, et al. Lanthanum carbonate treatment, for up to 6 years, is not associated with adverse effects on the liver in patients with chronic kidney disease Stage 5 receiving hemodialysis. Clin Nephrol 2009;71:286-95
   PubMed Web of Science ®Google Scholar
• Spasovski GB, Sikole A, Gelev S, et al. Evolution of bone and plasma concentration of lanthanum in dialysis patients before, during 1 year of treatment with lanthanum carbonate and after 2 years of follow-up. Nephrol Dial Transplant 2006;21(8):2217-24
   PubMed Web of Science ®Google Scholar
• Wilson R, Zhang P, Smyth M, Pratt R. Assessment of survival in a 2-year comparative study of lanthanum carbonate versus standard therapy. Curr Med Res Opin 2009;25(12):3021-8
   PubMed Web of Science ®Google Scholar
• de Francisco MAL, Rodriquez M. Magnesium–its role in CKD. Nefrologia 2013;33(3):389-99
   PubMed Web of Science ®Google Scholar
• Liabeuf S, Okazaki H, Desjardines L, et al. Vascular calcification in chronic kidney disease: are biomarkers useful for probing the pathobiology and the health risks of this process in the clinical scenario? Nephrol Dial Transplant 2014;29(7):1275-84
   PubMed Web of Science ®Google Scholar
• Shanahan CM. Vascular calcification. Curr Opin Nephrol Hypertens 2005;14:361-7
   PubMed Web of Science ®Google Scholar
• Sakagushi Y, Fujii N, Shoji T, et al. Magnesium modifies the cardiovascular mortality risk associated with hyperphosphatemia in patients undergoing hemodialysis: a cohort study. PLoS ONE 2014;9(12):e116273
   Google Scholar
• Hutchison AJ, Smith CP, Brenchley PE. Pharmacology, efficacy and safety of oral phosphate binders. Nat Rev Nephrol 2011;7(6):578-89
   PubMed Web of Science ®Google Scholar
• Guillot AP, Hood VL, Runge CF, Gennari FJ. The use of magnesium-containing phosphate binders in patients with end-stage renal disease on maintenance hemodialysis. Nephron 1982;30(2):114-17
   PubMed Web of Science ®Google Scholar
• Tzanakis IP, Papadaki AN, Wei M, et al. Magnesium carbonate for phosphate control in patients on hemodialysis. A randomized controlled trial. Int Urol Nephrol 2008;40(1):193-201
   PubMed Web of Science ®Google Scholar
• Massy ZA, Drueke TB. Magnesium and outcomes in patients with chronic kidney disease: focus on vascular calcification, atherosclerosis and survival. Clin Kidney J 2012;5(Suppl 1):i52-61
   Google Scholar
• Locatelli F, Dimkovic N, Pontoriero G, et al. Effect of MCI-196 on serum phosphate and cholesterol levels in hemodialysis patients with hyperphosphatemia: a double-blind, randomized, placebo-controlled study. Nephrol Dial Transplant 2010;25(2):574-81
   PubMed Web of Science ®Google Scholar
• Hertel J, Locatelli F, Spasovski G, et al. Randomized, Double-Blind, Placebo-Controlled, Withdrawal Study of Colestilan after Dose Titration in Chronic Kidney Disease Dialysis Patients with Hyperphosphatemia. Nephron 2015; in press
   PubMed Web of Science ®Google Scholar
• Locatelli F, Spasovski G, Dimkovic N, et al. The effects of Colestilan versus placebo and sevelamer in patients with CKD 5D and hyperphosphatemia: a 1-year prospective randomized study. Nephrol Dial Transplant 2014;29(5):1061-73
   PubMed Web of Science ®Google Scholar
• Locatelli F, Dimkovic N, Spasovski G. Efficacy of colestilan in the treatment of hyperphosphataemia in renal disease patients. Expert Opin Pharmacother 2014;15(10):1475-88
   PubMed Web of Science ®Google Scholar
• Wuthrich RP, Chonchol M, Covic A, et al. Randomized clinical trial of the ironbased phosphate binder PA21 in hemodialysis patients. Clin J Am Soc Nephrol 2013;8:280-9
   PubMed Web of Science ®Google Scholar
• Floege J, Covic AC, Ketteler M, et al. A phase III study of the efficacy and safety of a novel iron-based phosphate binder in dialysis patients. Kidney Int 2014;86(3):638-47
   PubMed Web of Science ®Google Scholar
• Dwyer JP, Sika M, Schulman G, et al. Collaborative Study Group. Dose response and efficacy of ferric citrate to treat hyperphosphatemia in hemodialysis patients: a short-term randomized trial. Am J Kidney Dis 2013;61:759-66
   PubMed Web of Science ®Google Scholar
• Floege J, Covic AC, Ketteler M, et al. Long-term effects of the iron-based phosphate binder, sucroferric oxyhydroxide, in dialysis patients. Nephrol Dial Transplant 2015;30(6):1037-46
   PubMed Web of Science ®Google Scholar
• Mutell R, Rubin J, Bond T, et al. Reduced use of erythropoiesis stimulating agents and intravenous iron with ferric citrate: a managed care cost-offset model. Int J Nephrol Renovasc Dis 2013;6:79-87
   PubMedGoogle Scholar
• Thomas A, Peterson LE. Reduction of costs for anemiamanagement drugs associated with the use of ferric citrate. Int J Nephrol Renovasc Dis 2014;7:191-201
   PubMedGoogle Scholar
• Gupta A. Ferric citrate hydrate as a phosphate binder and risk of aluminum toxicity. Pharmaceuticals (Basel) 2014;7:990-8
   PubMedGoogle Scholar
• Shin S, Lee S. Niacin as a drug repositioning candidate for hyperphosphatemia management in dialysis patients. Ther Clin Risk Manag 2014;10:875-83
   PubMed Web of Science ®Google Scholar
• Cheng SC, Young DO, Huang Y, et al. A randomized, double-blind, placebo controlled trial of niacinamide for reduction of phosphorus in hemodialysis patients. Clin J Am Soc Nephrol 2008;3:1131-8
   PubMed Web of Science ®Google Scholar
• Maccubbin D, Tipping D, Kuznetsova O, et al. Hypophosphatemic effect of niacin in patients without renal failure: a randomized trial. Clin J Am Soc Nephrol 2010;5:582-9
   PubMed Web of Science ®Google Scholar
• Takahashi Y, Tanaka A, Nakamura T, et al. Nicotinamide suppresses hyperphosphatemia in hemodialysis patients. Kidney Int 2004;65(3):1099-104
   PubMed Web of Science ®Google Scholar
• Chiu YW, Teitelbaum I, Misra M, et al. Pill burden, adherence, hyperphosphatemia, and quality of life in maintenance dialysis patients. Clin J Am Soc Nephrol 2009;4:1089-96
   PubMed Web of Science ®Google Scholar
• Karamanidou C, Clatworthy J, Weinman J, Horne R. A systematic review of the prevalence and determinants of nonadherence to phosphate binding medication in patients with end-stage renal disease. BMC Nephrol 2008;9:2
   PubMed Web of Science ®Google Scholar
• Arenas MD, Malek T, Gil MT, et al. Challenge of phosphorus control in hemodialysis patients: a problem of adherence? J Nephrol 2010;23(5):525-34
   PubMed Web of Science ®Google Scholar